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Abstract
Background: It has recently become apparent that neuroinflammation may play a significant role in
Parkinson's disease (PD). This is also the case in animal paradigms of the disease. The potential
neuroprotective action of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 (EX-4), which
is protective against cytokine mediated apoptosis and may stimulate neurogenesis, was investigated In
paradigms of PD.
Methods: Two rodent 'models' of PD, 6-hydroxydopamine (6-OHDA) and lipopolysaccaride (LPS), were
used to test the effects of EX-4. Rats were then investigated in vivo and ex vivo with a wide range of
behavioural, neurochemical and histological tests to measure integrity of the nigrostriatal system.
Results: EX-4 (0.1 and 0.5 μg/kg) was given seven days after intracerebral toxin injection. Seven days later
circling behaviour was measured following apomorphine challenge. Circling was significantly lower in rats
given EX-4 at both doses compared to animals given 6-OHDA/LPS and vehicle. Consistent with these
observations, striatal tissue DA concentrations were markedly higher in 6-OHDA/LPS + EX-4 treated rats
versus 6-OHDA/LPS + vehicle groups, whilst assay of L-DOPA production by tyrosine hydroxylase was
greatly reduced in the striata of 6-OHDA/LPS + vehicle rats, but this was not the case in rats co-
administered EX-4. Furthermore nigral TH staining recorded in 6-OHDA/LPS + vehicle treated animals
was markedly lower than in sham-operated or EX-4 treated rats. Finally, EX-4 clearly reversed the loss of
extracellular DA in the striata of toxin lesioned freely moving rats.
Conclusion: The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once
established, suggests that pharmacological manipulation of the GLP-1 receptor system could have
substantial therapeutic utility in PD. Critically, in contrast to other peptide agents that have been
demonstrated to possess neuroprotective properties in pre-clinical models of PD, EX-4 is in current
clinical use in the management of type-II diabetes and freely crosses the blood brain barrier; hence,
assessment of the clinical efficacy of EX-4 in patients with PD could be pursued without delay.
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Background
The well-characterised features of Parkinson's disease
(PD) are largely the result of a selective degeneration of
nigrostriatal neurons, greatly reduced synthetic capacity
for dopamine and a consequent failure to engage striatal
dopamine receptors [1]. Before the disease presents clini-
cally, death of nigrostriatal neurons occurs in the substan-
tia nigra pars compacta (SNc) 'silently', probably as a
result of concurrent apoptotic, excitotoxic, free-radical
mediated and neuroinflammatory events [2-5]. Environ-
mental and toxicological factors including bacterial tox-
ins,, in addition to the expression of candidate
'Parkinsonian' genes have all been proposed in the aetiol-
ogy of the disease [2,3,5]. Despite four decades of research
effort, a therapeutic strategy offering a cure for, or a means
of arresting the pathology of PD remains elusive. Estab-
lished drug-based therapies are essentially palliative and
not effective in all patients. Moreover, the side effect pro-
files of most drugs used in PD account for significant mor-
bidity, especially with chronic use, whilst the efficacy of
these treatments inevitably diminishes with time as cell
loss proceeds [6]. A need exists, therefore, for a novel ther-
apeutic approach, which is both affordable and more
importantly, provides the potential for arresting disease
progression as well as ameliorating symptoms. Since
apoptotic cell death is almost certainly one of the central
components in selective nigrostriatal neuronal death [7-9]
future therapeutic strategies could involve the targeted use
of bio-molecules with 'anti-apoptotic' properties. Alterna-
tively, a positive therapeutic effect could be produced by
molecules with neurotrophic properties or the ability to
stimulate neurogenesis of cells with a dopaminergic phe-
notype. However, for such an approach to have an
improved beneficial effect it would be desirable to stabi-
lize the destructive elements which favour neurodegener-
ation within the nigra. Compounds with anti-
inflammatory properties could be beneficial in this
respect. It has recently been observed that the glucagon-
like peptide-1 receptor (GLP-1R) agonist exendin-4 (EX-
4) shows neurotrophic [10] and 'neuroprotective' [11]
properties in cultured PC12 cells subjected to excitotoxic
stress. EX-4 – is also able to restore choline acetyl trans-
ferase positive cells following ibotenic acid lesions [11].
In addition Perry et al. [12] have found EX-4 to be neuro-
protective in a model of neuropathy. These observations
have led these authors to suggest that stimulation of GLP-
1 receptors (GLP-1R's) could be a therapeutic option in
neurodegenerative disorders such as PD. Indeed, EX-4 has
been shown to have anti-apoptotic properties against a
number of pro-inflammatory mediators in pancreatic β-
islet cells [13] which could be seen as indirect support for
this suggestion, particularly since neuroinflammation
may be a significant causative factor in PD [5]. Very
recently it has been observed that EX-4 reverses indicators
of NS damage in 6-hydroxydopamine (6-OHDA)
lesioned rats when given five weeks after toxin injection
[14]. This has been suggested to result from increased neu-
rogenesis originating in the subventricular zone (SVZ) by
EX-4 [14]. While clearly an important observation, the rel-
ative stability of the lesion at this time following 6-OHDA
[15] contrasts with the ongoing hostile environment
which prevails in PD patients or at a time point much
sooner after neurotoxin administration in animals. There-
fore, whether EX-4 mediated recovery would occur under
these conditions is as yet unclear. Neuropeptides, such as
glial cell derived neurotophic factor, are emerging as
potential therapeutic agents in PD [16]. We have recently
observed urocortin I (UCN), an endogenous peptide ago-
nist at corticotrophin releasing factor (CRF) receptors with
anti-inflammatory properties [17], to be protective in
rodent models of PD [18,19]. However, neither GDNF or
UCN are able to cross the blood brain barrier meaning
that they must either be delivered by neurosurgery or
appropriate agonists developed and validated. EX-4 is cur-
rently in clinical use in patients with type II diabetes and,
despite being a peptide with a molecular weight similar to
UCN, is readily able to enter the CNS [20]. Here we have
studied the effects of EX-4 on behavioral, neurochemical
and histological indices of nigrostriatal damage in both
the 6-hydroxydopamine (6-OHDA) or lipopolysaccaride
(LPS) lesioned rat. Two distinct models of PD were uti-
lized to diminish the possibility that EX-4 is active against
a single unique component of either model. We report
here a dramatic and potent reversal by EX-4 of established
PD-like lesions in the rat which could be of considerable
therapeutic significance if reproduced in the clinic.
Materials and methods
Materials
Desmethylimipramine, exendin-4, LPS (serotype E. Coli
0111:B4), pargyline, catalase, L-tyrosine, ferrous ammo-
nium sulphate, benserazide, 6 MPH4, 6-OHDA, LPS, apo-
morphine hydrochloride, 3-iodo-L-tyrosine, D-tyrosine
and tyrosine hydroxylase were all obtained from Sigma,
UK. Apomorphine and 6-OHDA were dissolved in 2.0%
w/v ascorbic acid, whilst UCN solid was initially dissolved
in 70% ethanol and further diluted in saline to 1 × 10-8 M
stock concentration. All drugs, apart from LPS and 6-
OHDA were injected in a volume of 0.1 ml/100 g body
weight. Rabbit polyclonal anti-rat TH IgG was obtained
from Calbiochem. Horseradish peroxidase (HRP) conju-
gated goat anti-rabbit IgG was obtained from Cell Signal-
ing, MA. Biotinylated swine anti-rabbit IgG was obtained
from Dako, Denmark. ABC complex was purchased from
Vector Laboratories, UK. All other reagents were of Analar
or HPLC grade.
Surgical procedures
An overview of the experimental protocols used in the
present series of experiments is shown in figure 1. NoteJournal of Neuroinflammation 2008, 5:19 http://www.jneuroinflammation.com/content/5/1/19
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that groups of rats went through all the procedures indi-
cated from initial toxin injection to ex vivo neurochemistry
and histology. Experiments were carried out in accordance
with the Animals (Scientific Procedures) Act UK (1986).
Male Wistar rats (210–240 g) were group housed and
access to food and water was ad libitum. Care was taken to
minimize animal usage and typically, tissue was used in
several different assay paradigms. Prior to surgery, ani-
mals to be lesioned with 6-OHDA received pargyline (50
mg/kg, i.p.) and desmethylimipramine (25 mg/kg, i.p.),
in order to maximize the selectivity of the toxin for
dopaminergic neurons. Animals were anaesthetized with
isofluorane (4% for induction, 1.5% for maintenance),
secured in a stereotaxic frame (David Kopf, US) and given
injections of 6-OHDA (8 μg/4 μl of saline with 1% ascor-
bic acid) injected into the right medial forebrain bundle
(from bregma in mm; A -4.3, L 1.4 and V 8.2) while LPS
(2 μg/2 μl saline) was injected into the substantia nigra
pars compacta (SNc; from bregma in mm; A -5.2, L 2.2
and V 8.3). Seven days later rats were administered EX-4
(0.1 or 0.5 μg/kg i.p, twice daily) dissolved in 0.9% saline
for a period of seven days.
Assessment of nigrostriatal lesion severity following 
apomorphine challenge
All animals received an apomorphine challenge (APO; 0.5
mg/kg sc.) in order to assess lesion severity as previously
described [21]. Animals were placed in a circular test
arena and following a short period of acclimatization,
injected with the dopaminergic agonist. Contraversive
turns were noted 20 min. post-injection and recorded
over a 120 s observation period. Only complete, 'tight'
turns were recorded. We have tested the value of observing
rats for longer periods of time (up to 60 min) and record-
ing rotations. Although, obviously, the number of rota-
tions was considerably higher using this protocol the
relative difference between groups was virtually identical
to sampling for the much shorter time period and the
overall methodology was far more time efficient.
In vivo microdialysis
Later that day rats were implanted with concentric dialysis
probes of a construction previously described [22]. Probes
were bilaterally implanted into each striatum (from
bregma; A +0.2, L 3.0, and ventral 8.2) and the following
day perfused with an artificial cerebrospinal fluid (aCSF)
solution (composition in mM: 2.5 KCl; 125 NaCl; 1.18
MgCl2; 1.26 CaCl2) as previously used [22] but without
addition of the 5-HT reuptake inhibitor citalopram. Fol-
lowing a 1 hour equilibration period four 30 min 'basal'
samples were collected prior to infusion of 100 mM
K+containing aCSF to evoke DA release. In the latter case
the concentration of Na+ was decreased accordingly to
maintain osmolarity of the aCSF.
Tissue dopamine assay
Animals received pargyline (50 mg/kg) 30 min prior to
sacrifice. Brains were removed, striata dissected and
homogenized in ice-cold phosphate buffer (pH 7.4). All
homegenates were split into two equal portions, with one
half of each treated with 0.2 M perchloric acid (1:10, w/v)
containing ascorbic acid (0.2 μM) and EDTA (0.2 μM), to
precipitate cell debris. These were then centrifuged at
9000 × g for 15 min at 4°C, supernatants passed through
a syringe filter (10 μm pore size) and whole tissue
dopamine levels estimated using HPLC with electrochem-
ical detection [22]. Brain blocs containing nigra were rap-
idly frozen and retained for immunohistochemistry.
Ex vivo tyrosine hydroxylase assay
TH activity was measured in the remaining homogenates,
using a modification of the method of Naoi et al. [23].
Aliquots were incubated with 200 μM L-tyrosine in a total
reaction mixture volume of 100 μl. This consisted of the
following components: 100 mM sodium acetate-acetic
acid buffer (pH 6.0), 2 mM ferrous ammonium sulphate,
1 mM 6 MPH4, 10 μg of catalase and 1 mM benserazide,
an inhibitor or aromatic L-amino acid decarboxylase
(AADC). 6 MPH4 solution was firstly made as 10 mM in 1
M mercaptoethanol. The incubation mixture, except for
tyrosine and the pteridin cofactor, was preincubated with
homegenates at 37°C for 5 min, and the reaction was ini-
tiated by addition of the L-tyrosine and 6 MPH4. After
incubation at 37°C for 10 min, the reaction was termi-
nated by addition of 100 μl perchloric acid (0.1 M, con-
taining 0.4 mM sodium metabisulphite and 0.1 mM
disodium EDTA). The sample was then vortexed and left
to stand on ice for 10 min, then centrifuged at 1000 × g for
10 min. The supernatant was diluted to 1 in 1000 with
mobile phase, then analyzed using HPLC-ED to measure
Flow diagram of the protocols used in the present study and the sequence in which they were performed Figure 1
Flow diagram of the protocols used in the present study and the sequence in which they were performed. Groups of rats were 
put through all of the procedures from toxin injection to ex vivo neurochemistry and histology.
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the amount of L-DOPA. As blank, a similar reaction mix-
ture containing D-tyrosine instead of the L-isomer and
100 μM 3-iodo-L-tyrosine was used [23].
Immunohistochemistry
Slide-mounted 10 μm cryostat sections from flash-frozen
rat brain blocs were removed from the freezer and allowed
to equilibrate to room temperature for 30 minutes, prior
to post fixation in 4% paraformaldehyde, containing 1%
gluteraldehyde for 5 minutes at 0°C. Following rinsing in
0.1 M PBS for 5 minutes, sections were dehydrated
through graded alcohols and endogenous peroxidase
activity was blocked by incubation in 0.3% H2O2 in meth-
anol for 10 minutes. The sections were then rehydrated
and non-specific immunoreactivity was blocked with
10% swine serum in PBS for 10 minutes. Sections were
then incubated in primary antibody (rabbit anti-rat TH
IgG) at 1:700 in PBS for 16 hours at 4°C. After rinsing, the
sections were incubated sequentially in biotinylated
swine anti-rabbit antibody 1:250 in PBS (Dako, Den-
mark) for 30 minutes at room temperature and ABC com-
plex following the manufacturer's instructions.
Immunoreactivity was visualized through incubation in
0.5 mg/ml 3-diaminobenzidine (DAB), containing
0.009% H2O2 for 2 minutes at room temperature. The sec-
tions were counterstained in Harris haematoxylin, dehy-
drated, cleared and mounted for microscopic
examination. Sections were viewed under light micros-
copy (×40 magnification). Digital images were captured
using a Leica DC500 system and the manufacturer's soft-
ware. For each animal, six successive nigral sections were
selected from both treated and contralateral side, taken
from a starting point of -5.5 mm relative to bregma, using
a total of six rats per group.
Data handling and analysis
Data obtained from apomorphine challenge, whole tissue
DA and TH assay studies were expressed as mean values ±
S.E.M. Data were subjected to one way or two way ANOVA
to identify overall trends, with a post hoc Bonferroni's mul-
tiple comparison test used to establish significant differ-
ences between the groups. Statistical analysis was
performed using a proprietary software package (Graph-
Pad Prism™). Numbers of animals used in experiments are
detailed in the figure legends. In all cases, comparisons
were made with respect to toxin/vehicle values. Statistical
significance was set at p < 0.05.
Results
Apomorphine (APO) induced circling is regarded as a
quantitative index of NS lesion severity [21] and thus, an
attenuation is predictive of potential anti-parkinsonian
activity. Our findings reveal that tight contralateral cir-
cling was clearly evident in 6-OHDA and LPS treated rats,
but this was dose-dependently attenuated by EX-4 (Fig.
2). Note that lesions are already well-advanced seven days
post injection [Fig. 2; [18,19]].
Striatal tissue DA concentration was substantially reduced
in 6-OHDA/LPS treated rats compared with sham or EX-4
groups (Fig. 3). This clearly indicates that EX-4 promotes
the retention or restoration of DA cells or cells with a
dopaminergic phenotype. In order to estimate functional
integrity of nigral neurons ipsilateral to injection sites, we
measured L-dihydroxyphenylalanine (L-DOPA) synthetic
capacity of striatal homogenates as well as tissue DA con-
tent. Ex vivo TH activities were significantly reduced in stri-
ata of 6-OHDA and LPS treated rats when compared to
sham treated rats and this was in marked contrast with
animals treated with both EX-4 doses, in which TH activi-
ties were near to control values (Fig 4).
Effect of EX-4 (0.1 and 0.5 μg/kg) on apomorphine-induced  rotational behaviour in 6-OHDA (upper panel) or LPS (lower  panel) lesioned rats Figure 2
Effect of EX-4 (0.1 and 0.5 μg/kg) on apomorphine-induced 
rotational behaviour in 6-OHDA (upper panel) or LPS (lower 
panel) lesioned rats. EX-4 was administered twice daily for 
seven days seven days after toxin injection. Circling was 
measured for 120 s 30 min after apomorphine injection. One 
way ANOVA values were 14.90, p < 0.001 (6-OHDA) and 
16.24, p < 0.001 (LPS). *indicates significant differences from 
UCN or sham injection sites (p < 0.01, n = 6 per group).
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Having established that administration of EX-4 prevents
the loss of NS function post-toxin in both rodent models,
we needed to ascertain whether this could be explained by
preservation of discrete nigral cells or alternatively
achieved through a substantial upregulation of TH pro-
tein in surviving cells. In order to test these possibilities, we
stained cryopreserved brain sections for TH immunoreac-
tivity and counted nigral cell bodies in the substantia
nigra. As shown in figures 5 and 6, 6-OHDA or LPS treat-
ment resulted in a near complete loss of TH+ cell bodies,
with very few accompanying dendrites remaining (Figures
show contralateral and ipsilateral nigral slices from the
same section). Rats similarly treated, but sacrificed after 7
days show a more modest loss of both NS cell bodies com-
pared to 14 day exposure [18,19]. As can be clearly seen,
EX-4 almost completely protected against loss of TH+ cells
when administered seven days following 6-OHDA or LPS
Effect of EX-4 (0.1 and 0.5 μg/kg) on striatal tissue DA con- tent in 6-OHDA (upper panel) or LPS (lower panel) lesioned  rats Figure 3
Effect of EX-4 (0.1 and 0.5 μg/kg) on striatal tissue DA con-
tent in 6-OHDA (upper panel) or LPS (lower panel) lesioned 
rats. EX-4 was administered twice daily for seven days seven 
days after toxin injection. One way ANOVA values were 
7.88, p < 0.001 (6-OHDA) and 6.67, p < 0.001 (LPS). *indi-
cates significant differences from EX-4 or sham injection sites 
(p < 0.01, n = 6 per group).
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Effect of EX-4 (0.1 and 0.5 μg/kg) on striatal tissue TH activ- ity in 6-OHDA (upper panel) or LPS (lower panel) lesioned  rats Figure 4
Effect of EX-4 (0.1 and 0.5 μg/kg) on striatal tissue TH activ-
ity in 6-OHDA (upper panel) or LPS (lower panel) lesioned 
rats. EX-4 was administered twice daily for seven days seven 
days after toxin injection. One way ANOVA values were 
7.88, p < 0.001 (6-OHDA) and 6.67, p < 0.001 (LPS). *indi-
cates significant differences from EX-4 or sham injection sites 
(p < 0.01, n = 6 per group).
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injection and this was particularly marked in rats given
LPS and the higher dose of EX-4. We are unclear as to the
reason for this other than to speculate that it may be the
result of the toxin used.
In order to evaluate the effect of EX-4 on extracellular DA
in the striatum we employed microdialysis in freely mov-
ing rats. We have assumed that extracellular DA represents
a functional index of DA release and this is supported by
our observation that 1 μM tetrodotoxin infusion
decreased dialysate DA by over 90% in sham treated rats
(data not shown). Both 6-OHDA and LPS greatly reduced
extracellular DA (Fig 7), which in a number of samples fell
below the limit of detection. In these cases we have
assigned a value of 5 fmol/10 μl, which constitutes the
level at which an unambiguously identifiable DA peak
can be resolved, in order to facilitate analysis of the data.
EX-4 dose-dependently reversed the depletion of extracel-
lular DA resulting from either 6-OHDA or LPS (Fig. 7).
This restoration of basal and evoked DA release indicates
a functional basis upon which motor movement is nor-
malized in apomorphine treated rats (Figs. 2 and 7).
Discussion
We have used a variety of measures, behavioural, neuro-
chemical and histological which indicate a clear protective
role for EX-4 against 6-OHDA or LPS mediated nigrostri-
atal lesions. These findings support a potential protective
role for EX-4 in these two paradigms of PD and clearly
demonstrate that when EX-4 is given after either 6-OHDA
or LPS, a comprehensive reversal of all selected markers of
nigrostriatal cellular loss results. This suggests that EX-4 is
able to rescue dopaminergic neurons once damage is
established or possibly stimulate neurogenesis of cells
with a dopaminergic phenotype. Of particular signifi-
cance is our finding that EX-4 is able to arrest and possibly
reverse NS lesions, once the neurodegenerative process has
commenced. This principle (if reproduced in the human
brain) would have obvious clinical significance since
patients generally present with symptoms only once
Photomicrographs of selected rat nigral sections, immunostained for TH Figure 5
Photomicrographs of selected rat nigral sections, immunostained for TH. Nigrostriatal cell bodies and dendrites appear dark 
brown/brown in sections. Sections A, C, E and are contralateral (untreated) nigra for comparison with ipsilateral (treated) 
nigra B, D, F. Key: B – 6-OHDA + vehicle, D – 6-OHDA + EX-4 0.1 μg/kg, F – 6-OHDA + EX-4 0.5 μg/kg. Bar is 100 μm. 
Sections are representative of 6 rats for each treatment.
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nigral neuronal loss reaches 70–80% of the total nigral
compliment, and striatal DA levels have fallen signifi-
cantly [24]. In the present study, EX-4 appears to 'reverse'
loss of TH+ immunoreactivity, since sections taken from
rats culled 7 days post-6-OHDA or LPS clearly show
greater numbers of TH+ structures than those from rats
killed 14 days after toxin injection [18,19].
The underlying cellular mechanism(s) responsible for our
finding is as yet, unclear, but other studies [10,11] suggest
that increased production of cAMP following GLP-1R
stimulation occurs. It has previously been reported that
EX-4 has anti-apoptotic properties thereby protecting pan-
creatic β-cells against pro-inflammatory insults. This may
be a significant finding in relation to PD since apoptosis
is an important mechanism in 6-OHDA neurotoxicity
[25] and human PD [7] and a role for neuroinflammation
in both animal models and PD itself is increasingly appar-
ent [4,5]. The use of the single-dose LPS PD model [26]
therefore increases the significance of our data. The effects
of EX-4 appear to be selectively directed towards the ipsi-
lateral lesioned side as the contralateral side showed no
obvious differences in the degree of TH staining between
saline and EX-4 treated rats and we have not found any
effect of EX-4 on TH staining in naïve rats (data not
shown). Moreover, in vitro estimation of DA formation
from L-DOPA in naïve rats treated for 7 days with EX-4
were very similar to untreated rats, further indicating a
lack of effect of the peptide on TH expression under these
conditions (data not shown). It is possible that EX-4 is
instigating  de novo neurogenesis, presumably from
recruited stem cells, as has been postulated in other stud-
Photomicrographs of selected rat nigral sections, immunostained for TH Figure 6
Photomicrographs of selected rat nigral sections, immunostained for TH. Nigrostriatal cell bodies and dendrites appear dark 
brown/brown in sections. Sections A, C, E and are contralateral (untreated) nigra for comparison with ipsilateral (treated) 
nigra B, D, F. Key: B – LPS + vehicle, D – LPS + EX-4 0.1 μg/kg, F – LPS + EX-4 0.5 μg/kg. Bar is 100 μm. Sections are repre-
sentative of 6 rats for each treatment.Journal of Neuroinflammation 2008, 5:19 http://www.jneuroinflammation.com/content/5/1/19
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ies [14,27], however, this is clearly speculative and
requires futher detailed investigation. The precise neuro-
anatomical site at which EX-4 acts is therefore as yet
unclear and studies, which we are currently undertaking,
on the cellular location of GLP1R's in both rodents and
patients are needed to shed further light on this.
Conclusion
Overall, our results significantly add to a growing knowl-
edge base, whereby EX-4 mediates a functional neuropro-
tection [10-12,14] with the crucial refinement that we
have demonstrated, for the first time, efficacy in two dis-
tinct in vivo models of a currently incurable neuropathol-
ogy. The apparent ability of EX-4 to arrest NS damage and
possibly stimulate remaining cells, suggests a novel mech-
anism, which if translated therapeutically would offer a
significant advance in PD treatment. This principle has
recently been proposed as an essential prerequisite for the
basis of a meaningful advance in PD therapy [28]. Vitally,
EX-4 has a long plasma half life compared with endog-
enous GLP-1 [20], readily crosses the blood brain barrier
and is in current clinical use. This suggests that EX-4
could, in principal, be trialed in PD patients with rela-
tively little delay.
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